General Information of Drug (ID: DMVNAYE)

Drug Name
MK-8521 Drug Info
Indication
Disease Entry ICD 11 Status REF
Type-2 diabetes 5A11 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DMVNAYE

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Approved Drug(s)
Drug(s) Targeting Glucagon (GCG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
PB-1023 DMZCI04 Type-2 diabetes 5A11 Phase 2 [2]
JNJ-64565111 DMVSUH1 Obesity 5B81 Phase 2 [2]
MEDI0382 DMSV60C Type-2 diabetes 5A11 Phase 2 [2]
PT320 DMZYKXN Parkinson disease 8A00.0 Phase 2 [3]
SAR425899 DM53IPE Diabetic complication 5A2Y Phase 1 [2]
ZP2929 DMRVDUM Type-1 diabetes 5A10 Phase 1 [2]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Targeting Glucagon receptor (GCGR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Glucagon recombinant DMFLUTR Hypoglycemia 5A41 Approved [4]
Dasiglucagon DM74SVE Hypoglycemia 5A41 Approved [5]
Retatrutide DM8WU0Q Obesity 5B81 Phase 3 [6]
LY2944876 DML6XWR Diabetic complication 5A2Y Phase 2 [7]
TT-401 DMRQ0SA Type-2 diabetes 5A11 Phase 2 [2]
LGD-6972 DMPL9KG Type-2 diabetes 5A11 Phase 2 [8]
PF-06291874 DMN94QM Type-2 diabetes 5A11 Phase 2 [9]
LY-2409021 DMZOIP4 Type-2 diabetes 5A11 Phase 2 [10]
REMD 477 DM13OVF Type-1 diabetes 5A10 Phase 2 [11]
Efinopegdutide DMAN2V2 Non-alcoholic steatohepatitis DB92.1 Phase 2 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Glucagon (GCG) TT0NUFM GLUC_HUMAN Co-agonist [2]
Glucagon receptor (GCGR) TT9O6WS GLR_HUMAN Co-agonist [2]

References

1 ClinicalTrials.gov (NCT02492763) A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004).
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869.
4 Glucagon receptor expression and glucagon stimulation of ghrelin secretion in rat stomach. Biochem Biophys Res Commun. 2007 Jun 15;357(4):865-70.
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
6 Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity? Expert Opin Investig Drugs. 2023 May;32(5):355-359.
7 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
8 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
9 Clinical pipeline report, company report or official report of pfizer.
10 Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015 Apr;17(4):414-22.
11 Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2018 May;20(5):1302-1305.
12 Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021 Sep;26(3):231-243.